Disability

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

The device is intended for initial treatment in the acute settingSARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc.…

2 years ago

Lifeward Unveils Newest Addition to Its AlterG Anti-Gravity Product Line – Introducing AlterG NEO

Elevate your practice and revolutionize patient care with the all-new user-friendly design and the same patented DAP technology for precise…

2 years ago

Linus Health Introduces Person-Centered Approach to Establish Clinically Meaningful Benefits and Personalized Brain Health Care

Scalable, systematic and automated process captures and monitors metrics based on patients' treatment priorities for managing Alzheimer's disease and related dementias…

2 years ago

NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

New molecule demonstrates efficacy in a challenging SCI modelExpanding pipeline into new indications of ischemic stroke and ALSVancouver, British Columbia--(Newsfile…

2 years ago

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who…

2 years ago

The IMA Group Continues to Expand Evaluation Services Senior Leadership Team

Move highlights division's growth; brings on noted industry experts Matt High and Elijah MarentetteTARRYTOWN, NY / ACCESSWIRE / June 25,…

2 years ago

Enlyte Launches Bundled Solution for Auto Bodily Injury Cost Containment

PrecisionDirect allows auto carriers to improve payment accuracy for provider services SAN DIEGO, June 20, 2024 /PRNewswire/ -- During claims settlements…

2 years ago

Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS)

Gap in non-oral prescriptions relative to AHS guidelines represents an opportunity to increase awareness of Tonix’s two FDA-approved non-oral treatments…

2 years ago

Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting

Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005…

2 years ago